title: Cardiac arterial pole alignment is sensitive to FGF8 signaling in the pharynx.
abstract: Morphogenesis of the cardiac arterial pole is dependent on addition of myocardium and smooth muscle from the secondary heart field and septation by cardiac neural crest cells. Cardiac neural crest ablation results in persistent truncus arteriosus and failure of addition of myocardium from the secondary heart field leading to malalignment of the arterial pole with the ventricles. Previously, we have shown that elevated FGF signaling after neural crest ablation causes depressed Ca2+ transients in the primary heart tube. We hypothesized that neural crest ablation results in elevated FGF8 signaling in the caudal pharynx that disrupts secondary heart field development. In this study, we show that FGF8 signaling is elevated in the caudal pharynx after cardiac neural crest ablation. In addition, treatment of cardiac neural crest-ablated embryos with FGF8b blocking antibody or an FGF receptor blocker rescues secondary heart field myocardial development in a time- and dose-dependent manner. Interestingly, reduction of FGF8 signaling in normal embryos disrupts myocardial secondary heart field development, resulting in arterial pole malalignment. These results indicate that the secondary heart field myocardium is particularly sensitive to FGF8 signaling for normal conotruncal development, and further, that cardiac neural crest cells modulate FGF8 signaling in the caudal pharynx.
authors.affiliation: Neonatal-Perinatal Research Institute, Division of Neonatology, Department of Pediatrics, Box 3179, Duke University Medical Center, Durham, NC 27710, USA. mhutson@duke.edu
authors.forename: Mary R
authors.initials: MR
authors.lastname: Hutson
authors.forename: Ping
authors.initials: P
authors.lastname: Zhang
authors.forename: Harriett A
authors.initials: HA
authors.lastname: Stadt
authors.forename: Asako K
authors.initials: AK
authors.lastname: Sato
authors.forename: Yin-Xiong
authors.initials: YX
authors.lastname: Li
authors.forename: Jarrett
authors.initials: J
authors.lastname: Burch
authors.forename: Tony L
authors.initials: TL
authors.lastname: Creazzo
authors.forename: Margaret L
authors.initials: ML
authors.lastname: Kirby
mesh_terms: D000818:Animals; D000906:Antibodies / Q000494:pharmacology / Q000627:therapeutic use; D004622:Embryo, Mammalian; D051524:Fibroblast Growth Factor 8 / Q000037:antagonists & inhibitors / Q000502:physiology*; D006321:Heart / Q000196:embryology* / Q000254:growth & development; D006330:Heart Defects, Congenital / Q000196:embryology / Q000209:etiology; D051379:Mice; D009024:Morphogenesis; D009432:Neural Crest / Q000002:abnormalities; D010614:Pharynx / Q000196:embryology* / Q000378:metabolism; D015398:Signal Transduction; D014339:Truncus Arteriosus, Persistent / Q000196:embryology / Q000209:etiology
chemical_list: D000906:Antibodies; C496457:Fgf8 protein, mouse; D051524:Fibroblast Growth Factor 8